Biocorp said this week that it received CE Mark approval for its Mallya device.
The Mallya device is a smart sensor that turns insulin pens into connected devices. It records treatment information and sends the data to a smartphone application that allows for an automatic recording of doses to manage diabetes treatment. The France-based company says Mallya reduces the need for manual logbooks.
Mallya can be integrated into continuous glucose monitoring systems and connected blood glucose systems, according to Biocorp. It is easy to install and does not impede the normal use of an insulin pen.
Biocorp expects to officially launch the Mallya device in the fall.
